PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTazarotene
Tazarotene
Arazlo, Avage, Duobrii, Fabior, Tazarotene, Tazorac (tazarotene) is a small molecule pharmaceutical. Tazarotene was first approved as Tazorac on 1997-06-13. It is used to treat acne vulgaris and psoriasis in the USA. The pharmaceutical is active against retinoic acid receptor beta, retinoic acid receptor gamma, and retinoic acid receptor alpha. In addition, it is known to target chemerin-like receptor 1 and chemerin-like receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Arazlo, Avage, Fabior, Tazarotene, Tazorac (discontinued: Tazarotene)
Combinations
Duobrii
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tazarotene
Tradename
Company
Number
Date
Products
TAZORACAllerganN-021184 RX2000-09-29
2 products, RLD, RS
AVAGEAllerganN-021184 RX2002-09-30
1 products, RLD, RS
TAZORACAllerganN-020600 RX1997-06-13
2 products, RLD, RS
ARAZLOBausch Health CompaniesN-211882 RX2019-12-18
1 products, RLD, RS
FABIORMayne GroupN-202428 RX2012-05-11
1 products, RLD, RS
Halobetasol propionate
+
Tazarotene
Tradename
Company
Number
Date
Products
DUOBRIIBausch Health CompaniesN-209354 RX2019-04-25
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
011312 niacinamide 4% / tazarotene 0.05%unapproved drug other2020-07-02
arazloNew Drug Application2023-09-26
clindamycin 1% / niacinamide 2% / tazarotene 0.05%unapproved drug other2019-05-09
duobriiNew Drug Application2020-01-01
fabiorNew Drug Application2024-05-09
hyaluronic acid sodium salt 0.5% / tazarotene 0.05%unapproved drug other2019-05-09
hyaluronic acid sodium salt 0.5% / tazarotene 0.1%unapproved drug other2019-05-06
niacinamide 4% / tazarotene 0.05%unapproved drug other2019-04-23
niacinamide 4% / tazarotene 0.1%unapproved drug other2019-05-09
tazarodexC2002632023-12-21
Show 2 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
psoriasisEFO_0000676D011565L40
acne vulgarisEFO_0003894D000152L70
pruritusHP_0000989D011537L29
inflammationMP_0001845D007249—
facial dermatoses—D005148—
foot dermatoses—D005533—
hand dermatoses—D006229—
scalp dermatoses—D012536—
leg dermatoses—D007868—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Tazarotene, Arazlo, Bausch
113114822038-05-11U-2368
116791162036-06-06DP
Halobetasol Propionate / Tazarotene, Duobrii, Bausch
102518952036-06-06DP
104267872036-06-06U-2625
116482562036-06-06DPU-2625
116791152036-06-06DPU-2625
88093072031-11-02DP
104785022031-11-02DPU-2625
118396562031-11-02U-2625
Tazarotene, Fabior, Mayne Pharma
88087162030-02-24DP
105688592030-02-24DPU-2760
106880712030-02-24DPU-2760
ATC Codes
D: Dermatologicals
— D05: Antipsoriatics
— D05A: Antipsoriatics for topical use
— D05AX: Other antipsoriatics for topical use in atc
— D05AX05: Tazarotene
— D05AX55: Tazarotene and ulobetasol
HCPCS
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acne vulgarisD000152EFO_0003894L701—13—5
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTazarotene
INNtazarotene
Description
Tazarotene is the ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin. It has a role as a keratolytic drug, a prodrug and a teratogenic agent. It is a retinoid, a thiochromane, a member of pyridines, an acetylenic compound and an ethyl ester. It is functionally related to a tazarotenic acid.
Classification
Small molecule
Drug classarotinoid derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Identifiers
PDB—
CAS-ID118292-40-3
RxCUI—
ChEMBL IDCHEMBL1657
ChEBI ID32184
PubChem CID5381
DrugBankDB00799
UNII ID81BDR9Y8PS (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CMKLR2
CMKLR2
Organism
Homo sapiens
Gene name
CMKLR2
Gene synonyms
GPR1
NCBI Gene ID
2825
Protein name
chemerin-like receptor 2
Protein synonyms
Chemerin chemokine-like receptor 2, Chemokine-like receptor 2, G protein-coupled receptor 1, G-protein coupled receptor 1, probable G-protein coupled receptor 1
Uniprot ID
Q6NVX4
Mouse ortholog
Cmklr2 (241070)
chemerin-like receptor 2 (Q8K087)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Tazarotene
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,116 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
753 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use